IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy b...
IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy
About this item
Full title
Author / Creator
Li, Song , Chen, Dianze , Guo, Huiqin , Yang, Yanan , Liu, Dandan , Yang, Chunmei , Bai, Xing , Zhang, Wei , Zhang, Li , Zhao, Gui , Tu, Xiaoping , Peng, Liang , Liu, Sijin , Song, Yongping , Jiang, Zhongxing , Zhang, Ruliang , Yu, Jifeng and Tian, Wenzhi
Publisher
United States: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
United States: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Abstract
This study evaluates the anti-tumor mechanism of IMM47, a humanized anti-CD24 mAb. Biolayer interferometry, ELISA and flow cytometry methods were used to measure the IMM47 binding, affinity, ADCC, ADCP, ADCT and CDC activities. In vivo therapeutical efficacy was measured in transplanted mouse models. IMM47 significantly binds granulocyt...
Alternative Titles
Full title
IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10576855
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10576855
Other Identifiers
ISSN
2516-4236
E-ISSN
2516-4236
DOI
10.1093/abt/tbad020
